FDA Advisory Panel Positive! Shares Punished.

The headline -- BioMimetic Therapeutics' (Nasdaq: BMTI  ) Augment Bone Graft Receives Positive Recommendation from FDA Advisory Committee -- sounds good, but the details tell a different story.

While technically the FDA panel vote came up positive, it was close -- just 10-8 in favor -- for both the efficacy of Augment and whether it had a favorable benefit-to-risk profile. Augment is a synthetic material that stimulates broken bones to grow back together.

But the advisory panel is just that, advisory, and the agency has the final say. Unfortunately for BioMimetic, the FDA didn't seem all that supportive of the clinical data testing Augment. The agency didn't seem convinced that Augment was any better than autologous grafts where bone from another part of the patient's body is used.

On Tuesday, after the FDA's briefing documents for the panel were released, BioMimetics stock lost 35% of its value. It recovered a little but has fallen again today after yesterday's vote.

Investors are right to be apprehensive about the likelihood of an approval. There are countless examples of the FDA turning down a drug or device despite a positive panel vote: Dendreon's (Nasdaq: DNDN  ) Provenge and InterMune's (Nasdaq: ITMN  ) Esbriet just to name a couple. Investors looking for a preview on the device side should keep their eyes on MELA Sciences (Nasdaq: MELA  ) , which is in the same boat with a positive panel yet a negative FDA pre-panel opinion.

That isn't to say Augment won't ever make it to market -- Provenge did, and Esbriet was approved in Europe -- but BioMimetic may have to run additional preapproval studies before the agency will sign off.

What's interesting about this case is that some members of the panel bashed the FDA for having an agenda against the device. If the vote was more in favor of Augment -- say, 14-4 or better -- I could see the agency taking their opinion into account, but with the vote being so close, I expect the agency won't change its stance much.

Unlike drugs, the FDA doesn't have goals for making decisions about the approval of medical devices. Management expects it could take about six months to hear back from the agency.

In the meantime, keep tabs on BioMimetic by adding it to your watchlist.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 18, 2011, at 11:56 AM, jrusso9722 wrote:

    There is no reason for 6 months to elapse on MelaFind. Power playing FDA should have a Congressional investigating panel, asking serious querstions.

  • Report this Comment On May 19, 2011, at 9:31 AM, HowardSadwin wrote:

    In 2005 Smith & Nephew's BHR was submitted for approval and was denied by 3-2 vote. Reason lacked suffecient data, and data supplied came from the Dr. who invented the product and Smith & Nephew. In 2006 Smith & Nephew resubmitted for approval with basically the same data and was approved 3-2.

    Seems odd this same company paid fines for paying off hospitals and doctors to use the BHR. By the way the doctor who invented the BHR and worked for Smith & Nephew at the time received over $100 million for his invention. Was their payoffs?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1494480, ~/Articles/ArticleHandler.aspx, 12/21/2014 9:44:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement